Maytansinoid DM4-Conjugated Humanized Monoclonal Antibody huC242 in Treating Patients With Solid Tumors

NCT00352131 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-colorectal Cancer
Pancreatic Cancer

Interventions

DRUG: HuC242-DM4

Sponsor

ImmunoGen, Inc.